



Published in final edited form as:

Handb Exp Pharmacol. 2017 ; 239: 363–378. doi:10.1007/164_2016_116.

Insights into the Role of Opioid Receptors in the GI Tract: Experimental Evidence and Therapeutic Relevance

James J. Galligan¹ and Catia Sternini²

¹Department of Pharmacology and Toxicology and the Neuroscience Program, Michigan State University, E. Lansing, MI 48824

²CURE/DDRC, Vache and Tamar Manoukian Division of Digestive Diseases, Departments of Medicine and Neurobiology, David Geffen School of Medicine, UCLA, Los Angeles, CA, 90095

Abstract

Opioid drugs are prescribed extensively for pain treatment but when used chronically they induce constipation that can progress to opioid-induced bowel dysfunction. Opioid drugs interact with three classes of opioid receptors: mu opioid receptors (MOR), delta opioid receptors (DOR) and kappa opioid receptors (KOR), but opioid drugs mostly target the MORs. Upon stimulation, opioid receptors couple to inhibitory Gi/Go proteins that activate or inhibit downstream effector proteins. MOR and DOR couple to inhibition of adenylate cyclase and voltage-gated Ca²⁺ channels and to activation of K⁺ channels resulting in reduced neuronal activity and neurotransmitter release. KOR couple to inhibition of Ca²⁺ channels and neurotransmitter release. In the gastrointestinal tract, opioid receptors are localized to enteric neurons, interstitial cells of Cajal and immune cells. In humans, MOR, DOR and KOR link to inhibition of acetylcholine release from enteric interneurons and motoneurons and purine/nitric oxide release from inhibitory motoneurons causing inhibition of propulsive motility patterns. MOR and DOR activation also result in inhibition of submucosal secretomotor neurons reducing active Cl⁻ secretion and passive water movement into the colonic lumen. Together, these effects on motility and secretion account for the constipation caused by opioid receptor agonists. Tolerance develops to the analgesic effects of opioid receptor agonists but not to the constipating actions. This may be due to differences in trafficking and downstream signaling in enteric nerves in the colon compared to the small intestine and in neuronal pain pathways. Further studies of differential opioid receptor desensitization and tolerance in subsets of enteric neurons may identify new drug or other treatment strategies of opioid-induced bowel dysfunction.

1. Introduction

Opioid receptor agonists are very effective in treating pain and they have powerful effects on gastrointestinal functions. Opioid receptor agonists produce their effects by interacting with opioid receptors, the MOR (the predominant receptor), DOR and KOR, belong to the family of G protein-coupled receptors (GPCRs) (Alex *et al.*, 2002; Williams *et al.*, 2013). Some opioid receptor agonists can also be used to treat gut motor and secretory disorders, especially diarrhea. However, chronic administration of opioid agonists cause constipation and in severe cases these drugs can cause the narcotic bowel syndrome (Grunkemeier *et al.*, 2007). With the increased use of prescription opioid receptor agonists for pain treatment,

there has been a parallel increase in the number of peripherally restricted opioid receptor antagonists that are used to reverse the gastrointestinal effects of opioid receptor agonists. At the same time peripherally restricted opioid receptor antagonists preserve the central nervous system mediated analgesic effects of the agonists. Finally, there are peripherally restricted opioid receptor agonist drugs that are used to treat diarrhea but have no abuse potential. This chapter will review the physiology and pharmacology of opioid receptors in the gut and the mechanisms by which opioid receptor agonists and antagonists alter gut function.

2. Localization of opioid receptors in the gastrointestinal tract

MOR, DOR and KOR are expressed by myenteric and submucosal plexus neurons in the enteric nervous system (ENS)(Bagnol *et al.*, 1997; Poonyachoti *et al.*, 2002; Ho *et al.*, 2003; Sternini *et al.*, 2004; Gray *et al.*, 2006; Poole *et al.*, 2011; Lay *et al.*, 2016), with some species differences. In the rat, MOR neurons are more abundant in the submucosal than myenteric plexus, whereas KOR are more numerous in the myenteric plexus, with both MOR and KOR myenteric neurons being more abundant in the stomach and proximal colon compared to other regions of the GI tract (Bagnol *et al.*, 1997). MOR and KOR are not co-expressed in the same rat enteric neurons (Gray *et al.*, 2006), whereas MOR and DOR extensively colocalize in rat and mouse enteric neurons (Gray *et al.*, 2006; Poole *et al.*, 2011). All three opioid receptors are expressed by interstitial cells of Cajal (ICCs) where MOR colocalizes with DOR or KOR in the rat GI tract (Bagnol *et al.*, 1997; Gray *et al.*, 2006). In the mouse GI tract, MOR and DOR but not KOR are expressed by ICC ((Kim *et al.*, 2016). In the guinea pig, MOR are localized to interneurons controlling the peristaltic reflex and to submucosal secretomotor neurons (Ho *et al.*, 2003; Lay *et al.*, 2016). In the guinea pig stomach, MOR are located in nitroergic inhibitory motoneurons and cholinergic secretomotor neurons (Lay *et al.*, 2016). In the guinea pig ileal myenteric plexus, MOR are localized to cholinergic, excitatory motor neurons and vasoactive intestinal peptide (VIP) expressing inhibitory motor neurons, and excitatory, cholinergic/VIPergic interneurons (Ho *et al.*, 2003; Lay *et al.*, 2016). The density of MOR nitroergic neurons is much higher than that of MOR cholinergic neurons in the myenteric plexus of both the proximal (Anselmi and Sternini, unpublished), and distal colon (Anselmi and Sternini, unpublished; Lay *et al.*, 2016). In the submucosal plexus, MOR are confined to VIP non-cholinergic secretomotor neurons of the ileum and distal colon (Lay *et al.*, 2016). MOR are not expressed by intrinsic primary afferent neurons (IPANs) at least in the guinea pig intestine (Ho *et al.*, 2003; Lay *et al.*, 2016). Finally, MOR nerve fibers are dense in the muscle layers often in close association with ICCs (Ho *et al.*, 2003). Both DOR and KOR have been reported in guinea pig enteric neurons with DOR being localized to myenteric and submucosal neurons and to varicose nerve fibres surrounding nerve cell bodies and the mucosal glands. KOR is confined to the myenteric plexus, where it is localized to neurons and nerve fibers supplying the muscle layers (Sternini *et al.*, 2004). In the mouse gut, DOR expressing neurons are most abundant in the small intestine and include secretomotor and vasomotor neurons of the submucosal plexus and excitatory and inhibitory myenteric motoneurons in the small intestine, but DOR are expressed mostly by inhibitory motoneurons in the colon myenteric plexus (Poole *et al.*, 2011). Finally, in the human gut, MOR is localized to neuronal cell bodies and nerve fibers in both submucosal and myenteric ganglia of the small and large

intestine (Sternini *et al.*, 2004). The overall distribution of opioid receptors is consistent with their role in modulating gastrointestinal motility and secretion (see below).

Opioid receptors, particularly MOR, are expressed by immune cells, supporting a role of the opioid system in regulating intestinal inflammation and intestinal ischemia (Stefano *et al.*, 1996; Madden *et al.*, 1998; Philippe *et al.*, 2003; Sternini *et al.*, 2004; Philippe *et al.*, 2006; Saccani *et al.*, 2012; Anselmi *et al.*, 2015). Opioid receptor activation on immune cells can have indirect actions on enteric nervous system function by suppressing synthesis or release of inflammatory mediators (Hughes *et al.*, 2016). (Table 1)

3. Actions of opioid drugs on myenteric neurons and gut motility

Opioid receptors are G protein coupled receptors that activate multiple effector molecules. MOR and DOR expressed by myenteric nerve cell bodies couple to the G_i G-protein to cause inhibition of adenylate cyclase, reduced cyclic 3',5' adenosine monophosphate (cAMP) and reduced levels of protein kinase A (PKA) activation (Liu & Anand, 2001; Christie, 2008). MOR and DOR also couple to the G_o subtype of G-protein which links MOR and DOR to inhibition of Ca²⁺ channels and activation of K⁺ channels via a membrane delimited mechanism (Morita & North, 1982; Mihara & North, 1986; North *et al.*, 1987; Surprenant *et al.*, 1990; Tatsumi *et al.*, 1990; Shen & Surprenant, 1991). Inhibition of Ca²⁺ channels decreases neurotransmitter release from enteric nerves while activation of K⁺ channels causes membrane potential hyperpolarization and inhibition of action potential firing. KOR links via G_o to inhibition of nerve terminal Ca²⁺ channels causing decreased neurotransmitter release (Cherubini *et al.*, 1985; Cherubini & North, 1985).

Myenteric neurons control gut motility by releasing acetylcholine and substance P to cause muscle contraction (Brookes, 2001) and ATP/βNAD, nitric oxide, VIP to cause muscle relaxation (Jin *et al.*, 1996; Brookes, 2001; Hwang *et al.*, 2011). Motoneurons are controlled by interneurons which coordinate the timing of contraction and relaxation required for propulsive motility patterns such as peristalsis. Interneurons use acetylcholine as the primary excitatory neurotransmitter but ATP and 5-HT also contribute to myenteric fast excitatory synaptic transmission (Galligan *et al.*, 2000).

Studies in human colon have shown that morphine acts at MOR and DOR to inhibit inhibitory neuromuscular transmission causing an increase in muscle tone and a decrease in propulsive motility (Bauer *et al.*, 1991). This is an important mechanism for the constipating effects of opioid receptor agonists. In addition, suppression of inhibitory neuromuscular transmission is likely responsible for the abdominal cramps caused by opioid receptor agonists. DOR also mediated inhibition of excitatory cholinergic and non-cholinergic neuromuscular transmission in the human distal colon (Chamouard *et al.*, 1994). Studies done by the same group also showed that KOR mediate inhibition of excitatory cholinergic and non-cholinergic and inhibitory neuromuscular transmission in the human colon ((Chamouard *et al.*, 1993).

Studies done in the mouse myenteric plexus have revealed additional mechanisms of opiate action on enteric neurons (Smith *et al.*, 2012). Whole cell patch clamp studies using mouse

myenteric neurons maintained in primary culture showed that morphine could reduce action potential firing by coupling to inhibition of voltage-gated Na⁺ channels. This effect would suppress interneuronal and neuromuscular transmission (Smith *et al.*, 2012). Myenteric neurons in the guinea pig and mouse small intestine express nicotinic receptors composed of $\alpha 3$ and $\beta 4$ subunits and these receptors mediate most fast excitatory postsynaptic potentials in the myenteric plexus (Zhou *et al.*, 2002; Gade *et al.*, 2016). Studies of mouse small intestinal myenteric neurons maintained in primary culture showed that nicotine-induced inward currents were larger in neurons exposed to morphine for 16–24 hours compared to neurons exposed to morphine for 1 hour. An $\alpha 3\beta 4$ nicotinic receptor agonist increased fecal pellet output in mice treated chronically but not acutely with morphine. These data suggest that tolerance to the inhibitory effects of morphine on gut motility may be due in part to upregulation of $\alpha 3\beta 4$ nicotinic receptors on small intestinal myenteric neurons (Gade *et al.*, 2016).

Recent studies have shown that activation of MOR and DOR but not KOR inhibits pacemaker potentials in mouse intestinal ICC maintained in primary culture. This effect was blocked by glibenclamide, a K⁺ ATP channel inhibitor and by guanylate cyclase and protein kinase G (PKG) inhibitors. These data indicate that MOR and DOR agonists activate K⁺ ATP channels *via* a cGMP/PKG dependent pathway to inhibit ICC function at least in the mouse intestine (Kim *et al.*, 2016). Disruption of pacemaker potentials would disrupt propulsive motility patterns and this would contribute to the constipating effects of opioid receptor agonists.

4. Actions of opioid drugs on submucosal neurons and intestinal secretion

Opioid receptor agonists inhibit colonic water and electrolyte secretion which contributes to opioid-induced constipation. Water and electrolyte (Cl⁻) secretion by enterocytes is stimulated by submucosal secretomotor neurons that release Ach and VIP from nerve endings in close apposition to the enterocytes (Brookes, 2001). Enterocytes express muscarinic cholinergic receptors and VPAC1 and VPAC2 receptors for VIP ((Banks *et al.*, 2005). Intestinal water secretion occurs in response to activation of enterocyte Cl⁻ channels including the cystic fibrosis transport regulator (CFTR) and CIC2 channels (Fei *et al.*, 2010; Kopic *et al.*, 2010). Opioid agonists acting at MOR and DOR on secretomotor neurons suppress Ach and VIP release resulting in a decrease in Cl⁻ secretion and osmotic water movement (North *et al.*, 1987; Fei *et al.*, 2010; Kopic *et al.*, 2010).

5. Opioid receptor trafficking, signaling cascades and tolerance development

MOR agonists activate GPCR-dependent pathways that regulate ion channels and adenylyl cyclase, or G protein-independent pathways that include scaffolding molecules and kinases (ERK and JNK). Activation of multiple signaling pathways may reflect agonist selectivity for GPCRs or agonist-selective MOR signaling (Williams *et al.*, 2013). Opioid receptor agonists initiate a cascade of events including phosphorylation of the opioid receptor by G

protein receptor kinases (GRKs) that promote receptor interaction with β -arrestins (β -arrestin 1 and 2). Activation of β -arrestin-2 in the ENS uncouples MOR from G proteins, causing internalization of the MOR through clathrin-coated pits and subsequent intracellular trafficking to the endosome (Sternini, 2001; Claing *et al.*, 2002; Williams *et al.*, 2013). The receptor is dephosphorylated in the endosome causing β -arrestin-2 to fall off the receptor which is then recycled back to the plasma membrane (Sternini, 2001; Claing *et al.*, 2002; Williams *et al.*, 2013). Phosphorylation, endocytosis, intracellular sorting and recycling are important regulatory processes that mediate desensitization, downregulation and resensitization, events that modulate cellular responsiveness. However, there are differences in the trafficking and recycling pattern depending on the neuron, agonist and duration of stimulation. In enteric neurons, *in vitro* and *in vivo*, MOR undergo rapid concentration-dependent and ligand-selective internalization that persists for as short as 2 hours (Lay *et al.*, 2016) or can last 4–6 hours (Minnis *et al.*, 2003). Internalized MORs can recycle back to the cell surface, a process that does not require new receptor synthesis. When recycled back to the membrane, MOR can internalize again with little or no loss of total receptor numbers (Minnis *et al.*, 2003). MOR internalization is induced by endogenous opioids, such as enkephalins and endomorphins, by the MOR agonist DAMGO (DAla²,N-Me-Phe⁴,Gly-^o15 enkephalin) that does not cross the blood-brain barrier, by most opiates, including etorphine and fentanyl (Sternini *et al.*, 1996; Minnis *et al.*, 2003) and by loperamide, a peripherally acting MOR agonist (Lay *et al.*, 2016). By contrast, morphine does not induce receptor internalization under the same conditions, even at concentrations that exceed those inducing maximal inhibition of neurogenic stimulation evoked smooth muscle contraction or inhibition of cAMP formation. The resistance of morphine-activated MORs to internalization has led to the proposal that internalization might protect against tolerance, since morphine has higher propensity to induce tolerance than opiates which induce efficient MOR internalization (e.g. etorphine or fentanyl) (Martini & Whistler, 2007). However, this idea has been challenged by the observation that morphine acquires the ability to induce pronounced MOR internalization in enteric neurons chronically treated with morphine *in vivo* (guinea pig) and *in vitro* (rat) (Patierno *et al.*, 2011; Duraffourd *et al.*, 2014). These differences in MOR internalization in response to morphine might be due to differences in the intracellular levels of proteins involved with receptor trafficking. Indeed, the internalization of morphine-activated MORs in neurons chronically exposed to morphine is accompanied by increased dynamin expression and translocation from the intracellular pool to the membrane. This response is prevented by treatment with a dynamin inhibitor or neuronal transfection with a mutant dynamin, in the absence of a change in β -arrestin levels (Duraffourd *et al.*, 2014). By contrast, in enteric neurons chronically exposed to fentanyl, morphine-activated MORs do not internalize and dynamin localization and levels are unchanged (Anselmi *et al.*, 2013). DAMGO, a selective MOR agonist with high internalizing efficiency, retains its ability to induce MOR internalization in neurons chronically stimulated with either morphine or fentanyl. This result indicates that chronic activation of MOR does not impair receptor trafficking in enteric neurons (Patierno *et al.*, 2011; Anselmi *et al.*, 2013). Different ligands might also affect the recycling pathways as suggested by the report that internalized MORs remain in the cytoplasm for at least 2 hours following stimulation with loperamide while DAMGO- and morphiceptin- (MOR agonist) activated receptors recycle back to the membrane within 2 hours (Lay *et al.*, 2016). Others

have shown that agonist-stimulated MOR can remain internalized up to 6 hours before recycling back to the membrane (Minnis *et al.*, 2003). Interestingly, MOR is more abundant in the cytoplasm of unstimulated enteric neurons in the colon compared to the small intestine (Anselmi and Sternini, unpublished). This finding, together with the different proportion of MOR excitatory and inhibitory enteric neurons in the small and large intestine, with higher ratio of excitatory MOR neurons in the ileum and higher percentage of MOR inhibitory neurons in the colon, could provide some explanation why the ileum but not the colon develops tolerance following chronic treatment with morphine (Ross *et al.*, 2008)(see below).

DORs also undergo agonist-stimulated internalization in enteric neurons. Internalization occurs in the soma and neurites and is blocked selectively by a DOR antagonist and is dynamin-dependent (Poole *et al.*, 2011). However, unlike MOR, DORs do not recycle to the cell surface and are degraded in lysosomes. Replenishment of DORs at the cell membrane occurs 6–16 hours later and requires synthesis of new receptors. The sustained receptor downregulation might play a role in long-lasting tolerance to DOR agonists (Poole *et al.*, 2011). Furthermore, since MOR and DOR co-localize in enteric neurons, we can speculate that heterodimerization might play a role in regulating the neuronal response to chronic use of opioid drugs, since there is evidence that opioid receptor dimerization or heterodimerization modulate receptor function (Jordan & Devi, 1999; Gomes *et al.*, 2004).

As described above, receptor phosphorylation results in acute receptor desensitization that develops within 1 minute of receptor activation. Phosphorylated receptors then undergo internalization and intracellular trafficking that induce late desensitization, which is followed by recycling so the receptors can be reactivated or degradation into lysosomes thus resulting in downregulation (Martini & Whistler, 2007; Williams *et al.*, 2013). This canonical pathway for receptor desensitization does not follow for all opioid agonists as exemplified by morphine, which produces profound tolerance yet results in little or no internalization. Several theories have been proposed to explain these differences. This includes different signaling pathways of MOR phosphorylation by low and high efficacy opioid agonists. Morphine-induced analgesic tolerance can be reversed by protein kinase C (PKC) inhibitors suggesting that PKC and not GRK phosphorylation mediates morphine-induced tolerance, while the high-efficacy opioid agonist, DAMGO- induced tolerance is mediated via GRK (Bailey *et al.*, 2006). MOR agonists can be distinguished by their internalization profiles and downstream effectors, which reflects functional selectivity at GPCR or ligand-directed signaling. For instance, morphine, unlike DAMGO or fentanyl, does not induce phosphorylation of the downstream signaling mitogenactivated protein kinase /extracellular signal-regulated kinases 1 and 2 (MAPK/ERK) in normal enteric neurons. By contrast, both internalizing (e.g. morphine and derivatives) and noninternalizing opioids (e.g. DAMGO, fentanyl) activate MAPK/ERK in enteric neurons chronically treated with morphine (Duraffourd *et al.*, 2014), further emphasizing ligand and cell type differences in MOR signaling. Together, these findings support the concept that different receptor and signaling mechanisms contribute to the regulation of opioid drug actions in the gut.

6. Tolerance mechanisms and opioid-induced constipation

Tolerance develops quickly to the analgesic but not constipating effects of opioid receptor agonists. In addition, tolerance develops to the anti-transit effects of morphine in the small intestine but not in the colon (Ross *et al.*, 2008; Galligan & Akbarali, 2014). The mechanism responsible for this effect was addressed in experiments measuring contractions caused by repeated morphine applications to *in vitro* circular muscle/myenteric plexus rings from wild type mouse small intestine and colon (Kang *et al.*, 2012). Morphine-induced contraction of small intestinal circular muscle, but not colon circular muscle declined in amplitude with repeated morphine applications suggesting that morphine tolerance developed in the small intestine but not colon. However, when the same experiment was repeated in tissues from β -arrestin2 knock-out mice, morphine tolerance developed in small intestinal *and* colon circular muscle rings (Kang *et al.*, 2012). Similar data were obtained in guinea pig ileum and colon preparations *in vitro* where tolerance to the inhibitory effects of morphine on electrically evoked circular muscle contractions developed in ileal but not colon tissues (Kang *et al.*, 2012). It has also been found that intestinal levels of β -arrestin do not change following chronic (4–7 days) morphine treatment *in vivo* in guinea pigs or *in vitro* in rat ileum (Patierno *et al.*, 2011; Kang *et al.*, 2012; Duraffourd *et al.*, 2014) suggesting the involvement of additional mechanisms that do not depend on β -arrestin2 levels. Chronic morphine treatment triggers changes in proteins involved in MOR trafficking such as dynamin upregulation and translocation, and downstream signaling including ERK phosphorylation-dependent activation of the transcription factor, CREB. Furthermore, blockade of this signaling pathway prevents the development of gastrointestinal motility impairment induced by chronic morphine treatment (Duraffourd *et al.*, 2014). Thus chronic morphine treatment alters MOR downstream signaling in enteric neurons leading to opioid-induced constipation. There are ~31 splice variants of the OPRM-1 gene that encodes for the MOR (Pan, 2005). Alternative splicing occurs in humans and rodents suggesting that multiple mechanisms can contribute to tolerance to different opioid receptor agonists. Differences in the carboxy terminal (a target for GRK phosphorylation) in different receptor isoforms may activate different intracellular signaling pathways that can explain why crosstolerance to analgesia does not occur among different opioid agonists (Pasternak, 2001). The presence of differences in MOR mediating the central inhibition of GI transit were suggested by earlier pharmacological studies with MOR antagonist naloxonazine (Heyman *et al.*, 1988) where anti-transit effects of intrathecally administered morphine were blocked by the antagonist but not when morphine was delivered at supra-spinal levels *via* intracerebroventricular injections. This was in contrast to the inhibition by naloxanazine of the analgesic effects. More recently, Mori *et al.* (Mori *et al.*, 2013) suggested the differential activation of MOR at central and peripheral sites by morphine, oxycodone and fentanyl. Thus, identifying the specific isoforms in the gastrointestinal tract will be important to establish new receptor targets for treating opioidinduced bowel dysfunction.

A significant development in opioid receptor pharmacology has been the identification of biased agonism where drug- induced stimulation of G-protein signaling differs from its efficacy for β -arrestin2 signaling (Violin & Lefkowitz, 2007) or its bias towards the Gi/o proteins (Manglik *et al.*, 2016). As stated above, persistent opiate receptor signaling in the

colon via β -arrestin2, contributes to opioid induced-constipation. Likewise, prolonged MOR signaling and MAPK/ERK activation induced by long-term opioid treatment in the ileum together with the induction of CREB phosphorylation might also contribute to the development of opioid-induced constipation (Duraffourd *et al.*, 2014). Opioid agonists with reduced efficiency in recruiting β -arrestin2 have strong analgesic properties with reduced side effects such as respiratory depression and constipation (Raehal *et al.*, 2011). TRV130 is a G-protein biased ligand that causes less β -arrestin2 recruitment than morphine and with higher potency towards analgesic effects and reduced constipation (DeWire *et al.*, 2013). Similarly, a new drug, PZM21, has been discovered utilizing structure-based computational screening methodology, which has strong bias activity for Gi/o signaling and is an effective analgesic with reduced constipation and abuse liability (Manglik *et al.*, 2016). The potential role of biased ligands in long-term use is under investigation.

7. Drugs acting at opioid receptors in the gastrointestinal tract

Loperamide (Imodium).

Loperamide is a MOR agonist used to treat diarrhea with limited abuse liability. Loperamide is used to treat occasional episodes of diarrhea, (traveler's diarrhea) but it is also used to treat some IBS patients with diarrhea as their predominant symptom. Loperamide is a substrate for P-glycoprotein which is a widely expressed transporter protein (Vandenbossche *et al.*, 2010). Loperamide has limited oral bioavailability due to the activity of p-glycoprotein expressed by mucosal epithelial cells and it has limited blood brain barrier permeability due to the action of p-glycoprotein expressed by astrocytes and endothelial cells in the cerebral circulation (Davis *et al.*, 2014). Loperamide acts at MOR in the ENS causing decreased propulsive motility and intestinal secretion (Awouters *et al.*, 1983)(Ho *et al.*, 2003; Lay *et al.*, 2016).

While loperamide has been used safely for many years, there has been a recent increase in the number of loperamide overdoses and fatalities (Bishop-Freeman *et al.*, 2016). The increase in loperamide overdoses parallels the rise in the use and abuse of prescription opiate pain medications and the related resurgence in heroin addiction (Daniulaityte *et al.*, 2013). At supra-therapeutic blood levels, loperamide can block cardiac HERG K⁺ channels leading to potentially fatal arrhythmias (Eggleston *et al.*, 2016; Kang *et al.*, 2016; Vaughn *et al.*, 2016).

Naloxegol (Movantik).

Naloxone is a potent and very selective antagonist of opioid receptors, especially MOR. Naloxone is used by first responders to reverse the potentially fatal effects of an opiate overdose. Naloxone readily crosses the blood brain barrier to block central sites of action of opioid drugs responsible for the lethal effects of an overdose (cardiovascular and respiratory centers). Naloxone also blocks peripheral sites of opiates including the enteric nervous system. Naloxegol is a pegylated modification of naloxone. Naloxegol is a substrate for the blood brain barrier P-glycoprotein transporter and together with its large molecular weight (652 g/mol) limits naloxegol penetration across the blood brain barrier (Bui *et al.*, 2016; Leppert & Woron, 2016). Naloxegol is approved for treatment of opioid-induced

constipation especially in non-cancer pain patients (Chey *et al.*, 2014; Leppert & Woron, 2016).

Methylnaltrexone (Relistor).

Methylnaltrexone is a naltrexone analog with a quarternary amine group that is positively charged and this limits its blood brain barrier permeability (Bader *et al.*, 2013; Webster *et al.*, 2015). Therefore, methylnaltrexone can block peripheral MOR without affecting centrally mediated analgesia. Methylnaltrexone is effective in treating opioid-induced constipation in cancer and non-cancer chronic pain patients.

Eluxoladine (Viberzi).

GPCRs can form heterodimeric complexes that increase signaling options and pharmacological responses. For example, MOR and DOR form heteromeric complexes throughout the nervous system (Fujita *et al.*, 2015). MOR or DOR ligands can bind individually to the heteromeric receptor complex to activate the dimeric receptor but binding of a DOR antagonist will increase the activity of agonists at the MOR binding site (Gomes *et al.*, 2004). Eluxoladine has been approved recently for the treatment of diarrhea-predominant IBS (Lacy, 2016). Eluxoladine (known as mu/delta in the earlier literature) is a mixed MOR agonist/DOR antagonist (Wade *et al.*, 2012). Preclinical studies showed that eluxoladine had limited systemic bioavailability after oral administration and its actions were restricted to the gut wall. Eluxoladine inhibited propulsive motility *in vivo* and intestinal secretion *in vitro* in mice, but it did not inhibit the visceromotor response to colorectal balloon distention in rats *in vivo*. These results are consistent with a local gastrointestinal action of eluxoladine. Eluxoladine reduces diarrhea in IBS-diarrhea patients and constipation is rare (Lembo *et al.*, 2016). The beneficial effects of eluxoladine on gut motility may be related to biased signaling due to the mixed MOR agonist/DOR antagonist properties of the drug. Although evidence documenting MOR/DOR dimers in the gut is not available both receptors are expressed in the ENS. Agonist activation of enteric neuronal MOR initiates β -arrestin signaling and ERK phosphorylation which are likely to causes constipation. However, simultaneous ligand binding to a MOR/DOR heterodimer is coupled to G-protein signaling pathways not linked to constipation (Wade *et al.*, 2012).

8. SUMMARY AND CONCLUSIONS

Morphine and other MOR agonists cause constipation by disrupting neurotransmission in the ENS. This causes a reduction in propulsive motility and colonic secretion. Morphine and other agonists act at MOR, DOR and KOR to inhibit Ca^{2+} and Na^{+} channels and to activate K^{+} channels on enteric neurons. Receptor desensitization is a key component regulating opiate receptor signaling in the nervous system and β -arrestin and dynamin binding to activated opiate receptors causing receptor internalization, intracellular trafficking and desensitization. There are differences in β -arrestin signaling that are important for tolerance development to the analgesic effects of opioid receptor agonists. However, β -arrestin signaling does not link to opioid receptor desensitization and tolerance in the colon. This is likely one cellular/molecular mechanism responsible for opioid-induced bowel dysfunction. In addition, other proteins involved in receptor trafficking such as dynamin and GRKs are

likely to play an important role in the mechanisms initiating compensatory downstream events that contribute to opioid agonist induced side effects (Finn & Whistler, 2001; Martini & Whistler, 2007; Williams *et al.*, 2013, Finn, 2001 #3852). Development of opioid receptor agonists with biased agonism and identification of receptor isoforms as well as a better understanding of downstream signaling pathways in enteric neurons of different regions of the gastrointestinal tract require further study.

ACKNOWLEDGMENTS:

Supported by NIH DK094932 (JJG), NIH P30 DK41301, Imaging Core (CS)

REFERENCES

- Alex G, Clerc N, Kunze WA & Furness JB (2002) Responses of myenteric S neurones to low frequency stimulation of their synaptic inputs. *Neuroscience*, 110, 361–373. [PubMed: 11958877]
- Anselmi L, Huynh J, Duraffourd C, Jaramillo I, Vegezzi G, Saccani F, Boschetti E, Brecha NC, De Giorgio R & Sternini C (2015) Activation of mu opioid receptors modulates inflammation in acute experimental colitis. *Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society*, 27, 509–523. [PubMed: 25690069]
- Anselmi L, Jaramillo I, Palacios M, Huynh J & Sternini C (2013) Ligand-induced mu opioid receptor internalization in enteric neurons following chronic treatment with the opiate fentanyl. *J Neurosci Res*, 91, 854–860. [PubMed: 23553842]
- Awouters F, Niemegeers CJ & Janssen PA (1983) Pharmacology of antidiarrheal drugs. *Annu Rev Pharmacol Toxicol*, 23, 279–301. [PubMed: 6307123]
- Bader S, Durk T & Becker G (2013) Methylnaltrexone for the treatment of opioid-induced constipation. *Expert review of gastroenterology & hepatology*, 7, 13–26. [PubMed: 23265145]
- Bagnol D, Mansour A, Akil H & Watson SJ (1997) Cellular localization and distribution of the cloned mu and kappa opioid receptors in rat gastrointestinal tract. *Neuroscience*, 81, 579–591. [PubMed: 9300443]
- Bailey CP, Smith FL, Kelly E, Dewey WL & Henderson G (2006) How important is protein kinase C in mu-opioid receptor desensitization and morphine tolerance? *Trends Pharmacol Sci*, 27, 558–565. [PubMed: 17000011]
- Banks MR, Farthing MJ, Robberecht P & Burleigh DE (2005) Antisecretory actions of a novel vasoactive intestinal polypeptide (VIP) antagonist in human and rat small intestine. *Br J Pharmacol*, 144, 994–1001. [PubMed: 15711593]
- Bauer AJ, Sarr MG & Szurszewski JH (1991) Opioids inhibit neuromuscular transmission in circular muscle of human and baboon jejunum. *Gastroenterology*, 101, 970–976. [PubMed: 1679737]
- Bishop-Freeman SC, Feaster MS, Beal J, Miller A, Hargrove RL, Brower JO & Winecker RE (2016) Loperamide-Related Deaths in North Carolina. *J Anal Toxicol*. 40, 677–686. [PubMed: 27474361]
- Brookes SJ (2001) Classes of enteric nerve cells in the guinea-pig small intestine. *Anat Rec*, 262, 58–70. [PubMed: 11146429]
- Bui K, She F, Zhou D, Butler K, Al-Huniti N & Sostek M (2016) The effect of quinidine, a strong P-glycoprotein inhibitor, on the pharmacokinetics and central nervous system distribution of naloxegol. *J Clin Pharmacol*, 56, 497–505. [PubMed: 26248047]
- Chamouard P, Klein A, Martin E, Adloff M & Angel F (1993) Regulatory role of enteric kappa opioid receptors in human colonic motility. *Life sciences*, 53, 1149–1156. [PubMed: 8103909]
- Chamouard P, Rohr S, Meyer C, Baumann R & Angel F (1994) Delta-opioid receptor agonists inhibit neuromuscular transmission in human colon. *European journal of pharmacology*, 262, 33–39. [PubMed: 7813576]
- Cherubini E, Morita K & North RA (1985) Opioid inhibition of synaptic transmission in the guinea-pig myenteric plexus. *British journal of pharmacology*, 85, 805–817. [PubMed: 2412622]

- Cherubini E & North RA (1985) Mu and kappa opioids inhibit transmitter release by different mechanisms. *Proceedings of the National Academy of Sciences of the United States of America*, 82, 1860–1863. [PubMed: 2984670]
- Chey WD, Webster L, Sostek M, Lappalainen J, Barker PN & Tack J (2014) Naloxegol for opioid-induced constipation in patients with noncancer pain. *N Engl J Med*, 370, 2387–2396. [PubMed: 24896818]
- Christie MJ (2008) Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction. *British journal of pharmacology*, 154, 384–396. [PubMed: 18414400]
- Claing A, Laporte SA, Caron MG & Lefkowitz RJ (2002) Endocytosis of G protein-coupled receptors: roles of G protein-coupled receptor kinases and beta-arrestin proteins. *Prog Neurobiol*, 66, 61–79. [PubMed: 11900882]
- Daniulaityte R, Carlson R, Falck R, Cameron D, Perera S, Chen L & Sheth A (2013) “I just wanted to tell you that loperamide WILL WORK”: a web-based study of extramedical use of loperamide. *Drug Alcohol Depend*, 130, 241–244. [PubMed: 23201175]
- Davis TP, Sanchez-Covarubias L & Tome ME (2014) P-glycoprotein trafficking as a therapeutic target to optimize CNS drug delivery. *Adv Pharmacol*, 71, 25–44. [PubMed: 25307213]
- DeWire SM, Yamashita DS, Rominger DH, Liu G, Cowan CL, Graczyk TM, Chen XT, Pitis PM, Gotchev D, Yuan C, Koblish M, Lark MW & Violin JD (2013) A G protein-biased ligand at the mu-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. *The Journal of pharmacology and experimental therapeutics*, 344, 708–717. [PubMed: 23300227]
- Duraffourd C, Kumala E, Anselmi L, Brecha NC & Sternini C (2014) Opioid-Induced Mitogen-Activated Protein Kinase Signaling in Rat Enteric Neurons following Chronic Morphine Treatment. *PloS one*, 9, e110230. [PubMed: 25302800]
- Eggleston W, Clark KH & Marraffa JM (2016) Loperamide Abuse Associated With Cardiac Dysrhythmia and Death. *Ann Emerg Med*.
- Fei G, Raehal K, Liu S, Qu MH, Sun X, Wang GD, Wang XY, Xia Y, Schmid CL, Bohn LM & Wood JD (2010) Lubiprostone reverses the inhibitory action of morphine on intestinal secretion in guinea pig and mouse. *The Journal of pharmacology and experimental therapeutics*, 334, 333–340. [PubMed: 20406855]
- Finn AK & Whistler JL (2001) Endocytosis of the mu opioid receptor reduces tolerance and a cellular hallmark of opiate withdrawal. *Neuron*, 32, 829–839. [PubMed: 11738029]
- Fujita W, Gomes I & Devi LA (2015) Heteromers of mu-delta opioid receptors: new pharmacology and novel therapeutic possibilities. *British journal of pharmacology*, 172, 375–387. [PubMed: 24571499]
- Gade AR, Kang M, Khan F, Grider JR, Damaj MI, Dewey WL & Akbarali HI (2016) Enhanced Sensitivity of alpha3beta4 Nicotinic Receptors in Enteric Neurons after LongTerm Morphine: Implication for Opioid-Induced Constipation. *The Journal of pharmacology and experimental therapeutics*, 357, 520–528. [PubMed: 27068812]
- Galligan JJ & Akbarali HI (2014) Molecular physiology of enteric opioid receptors. *American journal of gastroenterology supplements*, 2, 17–21.
- Galligan JJ, LePard KJ, Schneider DA & Zhou X (2000) Multiple mechanisms of fast excitatory synaptic transmission in the enteric nervous system. *J Auton Nerv Syst*, 81, 97–103. [PubMed: 10869707]
- Gomes I, Gupta A, Filipovska J, Szeto HH, Pintar JE & Devi LA (2004) A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia. *Proceedings of the National Academy of Sciences of the United States of America*, 101, 5135–5139. [PubMed: 15044695]
- Gray AC, Coupar IM & White PJ (2006) Comparison of opioid receptor distributions in the rat ileum. *Life Sci*, 78, 1610–1616. [PubMed: 16289621]
- Grunkemeier DM, Cassara JE, Dalton CB & Drossman DA (2007) The narcotic bowel syndrome: clinical features, pathophysiology, and management. *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*, 5, 1126–1139; quiz 1121–1122. [PubMed: 17916540]

- Heyman JS, Williams CL, Burks TF, Mosberg HI & Porreca F (1988) Dissociation of opioid antinociception and central gastrointestinal propulsion in the mouse: studies with naloxonazine. *The Journal of pharmacology and experimental therapeutics*, 245, 238243.
- Ho A, Lievore A, Patierno S, Kohlmeier SE, Tonini M & Sternini C (2003) Neurochemically distinct classes of myenteric neurons express the μ -opioid receptor in the guinea pig ileum. *J Comp Neurol*, 458, 404–411. [PubMed: 12619074]
- Hughes PA, Costello SP, Bryant RV & Andrews JM (2016) Opioidergic effects on enteric and sensory nerves in the lower GI tract: basic mechanisms and clinical implications. *American journal of physiology. Gastrointestinal and liver physiology*, 311, G501–513. [PubMed: 27469369]
- Hwang SJ, Durnin L, Dwyer L, Rhee PL, Ward SM, Koh SD, Sanders KM & Mutafova-Yambolieva VN (2011) beta-nicotinamide adenine dinucleotide is an enteric inhibitory neurotransmitter in human and nonhuman primate colons. *Gastroenterology*, 140, 608–617 e606. [PubMed: 20875415]
- Jin JG, Murthy KS, Grider JR & Makhlof GM (1996) Stoichiometry of neurally induced VIP release, NO formation, and relaxation in rabbit and rat gastric muscle. *The American journal of physiology*, 271, G357–369. [PubMed: 8770052]
- Jordan BA & Devi LA (1999) G-protein-coupled receptor heterodimerization modulates receptor function. *Nature*, 399, 697–700. [PubMed: 10385123]
- Kang J, Compton DR, Vaz RJ & Rampe D (2016) Proarrhythmic mechanisms of the common anti-diarrheal medication loperamide: revelations from the opioid abuse epidemic. *Naunyn Schmiedebergs Arch Pharmacol*, 389, 1133–1137. [PubMed: 27530870]
- Kang M, Maguma HT, Smith TH, Ross GR, Dewey WL & Akbarali HI (2012) The role of beta-arrestin2 in the mechanism of morphine tolerance in the mouse and guinea pig gastrointestinal tract. *The Journal of pharmacology and experimental therapeutics*, 340, 567–576. [PubMed: 22129596]
- Kim HJ, Kim H, Jung MH, Kwon YK & Kim BJ (2016) Berberine induces pacemaker potential inhibition via cGMP-dependent ATP-sensitive K⁺ channels by stimulating mu/delta opioid receptors in cultured interstitial cells of Cajal from mouse small intestine. *Molecular medicine reports*, 14, 3985–3991. [PubMed: 27601272]
- Kopic S, Corradini S, Sidani S, Murek M, Vardanyan A, Foller M, Ritter M & Geibel JP (2010) Ethanol inhibits gastric acid secretion in rats through increased AMP-kinase activity. *Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology*, 25, 195–202.
- Lacy BE (2016) Emerging treatments in neurogastroenterology: eluxadolone - a new therapeutic option for diarrhea-predominant IBS. *Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society*, 28, 26–35. [PubMed: 26690872]
- Lay J, Carbone SE, DiCello JJ, Bunnett NW, Canals M & Poole DP (2016) Distribution and trafficking of the mu-opioid receptor in enteric neurons of the guinea pig. *American journal of physiology. Gastrointestinal and liver physiology*, 311, G252–266. [PubMed: 27365337]
- Lembo AJ, Lacy BE, Zuckerman MJ, Schey R, Dove LS, Andrae DA, Davenport JM, McIntyre G, Lopez R, Turner L & Covington PS (2016) Eluxadolone for Irritable Bowel Syndrome with Diarrhea. *N Engl J Med*, 374, 242–253. [PubMed: 26789872]
- Leppert W & Woron J (2016) The role of naloxegol in the management of opioid-induced bowel dysfunction. *Therap Adv Gastroenterol*, 9, 736–746.
- Liu JG & Anand KJ (2001) Protein kinases modulate the cellular adaptations associated with opioid tolerance and dependence. *Brain Res Brain Res Rev*, 38, 1–19. [PubMed: 11750924]
- Madden JJ, Whaley WL & Ketelsen D (1998) Opiate binding sites in the cellular immune system: expression and regulation. *Journal of neuroimmunology*, 83, 57–62. [PubMed: 9610673]
- Manglik A, Lin H, Aryal DK, McCorvy JD, Dengler D, Corder G, Levit A, Kling RC, Bernat V, Hubner H, Huang XP, Sassano MF, Giguere PM, Lober S, Da D, Scherrer G, Kobilka BK, Gmeiner P, Roth BL & Shoichet BK (2016) Structurebased discovery of opioid analgesics with reduced side effects. *Nature*, 537, 185–190. [PubMed: 27533032]

- Martini L & Whistler JL (2007) The role of mu opioid receptor desensitization and endocytosis in morphine tolerance and dependence. *Current opinion in neurobiology*, 17, 556–564. [PubMed: 18068348]
- Mihara S & North RA (1986) Opioids increase potassium conductance in submucous neurones of guinea-pig caecum by activating delta-receptors. *British journal of pharmacology*, 88, 315–322. [PubMed: 2873857]
- Minnis J, Patierno S, Kohlmeier SE, Brecha N, Tonini M & Sternini C (2003) Ligand-induced μ opioid receptor endocytosis and recycling in enteric neurons. *Neuroscience*, 119, 33–42. [PubMed: 12763066]
- Mori T, Shibasaki Y, Matsumoto K, Shibasaki M, Hasegawa M, Wang E, Masukawa D, Yoshizawa K, Horie S & Suzuki T (2013) Mechanisms that underlie mu-opioid receptor agonist-induced constipation: differential involvement of mu-opioid receptor sites and responsible regions. *The Journal of pharmacology and experimental therapeutics*, 347, 91–99. [PubMed: 23902939]
- Morita K & North RA (1982) Opiate activation of potassium conductance in myenteric neurons: inhibition by calcium ion. *Brain Res*, 242, 145–150. [PubMed: 7104724]
- North RA, Williams JT, Surprenant A & Christie MJ (1987) Mu and delta receptors belong to a family of receptors that are coupled to potassium channels. *Proceedings of the National Academy of Sciences of the United States of America*, 84, 5487–5491. [PubMed: 2440052]
- Pan YX (2005) Diversity and complexity of the mu opioid receptor gene: alternative pre-mRNA splicing and promoters. *DNA Cell Biol*, 24, 736–750. [PubMed: 16274294]
- Pasternak GW (2001) Incomplete cross tolerance and multiple mu opioid peptide receptors. *Trends Pharmacol Sci*, 22, 67–70. [PubMed: 11166849]
- Patierno S, Anselmi L, Jaramillo I, Scott D, Garcia R & Sternini C (2011) Morphine induces mu opioid receptor endocytosis in guinea pig enteric neurons following prolonged receptor activation. *Gastroenterology*, 140, 618–626. [PubMed: 21070774]
- Philippe D, Chakass D, Thuru X, Zerbib P, Tscicopoulos A, Geboes K, Bulois P, Bresse M, Vorng H, Gay J, Colombel JF, Desreumaux P & Chamaillard M (2006) Mu opioid receptor expression is increased in inflammatory bowel diseases: implications for homeostatic intestinal inflammation. *Gut*, 55, 815–823. [PubMed: 16299031]
- Philippe D, Dubuquoy L, Groux H, Brun V, Chuoi-Mariot MT, Gaveriaux-Ruff C, Colombel JF, Kieffer BL & Desreumaux P (2003) Anti-inflammatory properties of the mu opioid receptor support its use in the treatment of colon inflammation. *The Journal of clinical investigation*, 111, 1329–1338. [PubMed: 12727924]
- Poole DP, Pelayo JC, Scherrer G, Evans CJ, Kieffer BL & Bunnett NW (2011) Localization and regulation of fluorescently labeled delta opioid receptor, expressed in enteric neurons of mice. *Gastroenterology*, 141, 982–991 e988. [PubMed: 21699782]
- Poonyachoti S, Kulkarni-Narla A & Brown DR (2002) Chemical coding of neurons expressing δ - and κ -opioid receptor and type I vanilloid receptor immunoreactivities in the porcine ileum. *Cell Tissue Res*, 307, 23–33. [PubMed: 11810311]
- Raehal KM, Schmid CL, Groer CE & Bohn LM (2011) Functional selectivity at the mu opioid receptor: implications for understanding opioid analgesia and tolerance. *Pharmacological reviews*, 63, 1001–1019. [PubMed: 21873412]
- Ross GR, Gabra BH, Dewey WL & Akbarali HI (2008) Morphine tolerance in the mouse ileum and colon. *The Journal of pharmacology and experimental therapeutics*, 327, 561572.
- Saccani F, Anselmi L, Jaramillo I, Bertoni S, Barocelli E & Sternini C (2012) Protective role of mu opioid receptor activation in intestinal inflammation induced by mesenteric ischemia/reperfusion in mice. *J Neurosci Res*, 90, 2146–2153. [PubMed: 22806643]
- Shen KZ & Surprenant A (1991) Noradrenaline, somatostatin and opioids inhibit activity of single HVA/N-type calcium channels in excised neuronal membranes. *Pflugers Arch*, 418, 614–616. [PubMed: 1682876]
- Smith TH, Grider JR, Dewey WL & Akbarali HI (2012) Morphine decreases enteric neuron excitability via inhibition of sodium channels. *PloS one*, 7, e45251. [PubMed: 23028881]

- Stefano GB, Scharrer B, Smith EM, Hughes TK, Jr., Magazine HI, Bilfinger TV, Hartman AR, Fricchione GL, Liu Y & Makman MH (1996) Opioid and opiate immunoregulatory processes. *Crit Rev Immunol*, 16, 109–144. [PubMed: 8879941]
- Sternini C (2001) Receptors and transmission in the brain-gut axis: potential for novel therapies. III. μ opioid receptors in the enteric nervous system. *Am. J. Physiol*, 281, G8–G15.
- Sternini C, Patierno S, Selmer IS & Kirchgessner A (2004) The opioid system in the gastrointestinal tract. *Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society*, 16 Suppl 2, 3–16.
- Sternini C, Spann M, Anton B, Keith DE, Jr., Bunnett NW, von Zastrow M, Evans C & Brecha NC (1996) Agonist-selective endocytosis of μ opioid receptor by neurons *in vivo*. *Proc Natl Acad Sci USA*, 93, 9241–9246. [PubMed: 8799185]
- Surprenant A, Shen KZ, North RA & Tatsumi H (1990) Inhibition of calcium currents by noradrenaline, somatostatin and opioids in guinea-pig submucosal neurones. *The Journal of physiology*, 431, 585–608. [PubMed: 1983121]
- Tatsumi H, Costa M, Schimerlik M & North RA (1990) Potassium conductance increased by noradrenaline, opioids, somatostatin, and G-proteins: whole-cell recording from guinea pig submucous neurons. *The Journal of neuroscience : the official journal of the Society for Neuroscience*, 10, 1675–1682. [PubMed: 1970605]
- Vandenbossche J, Huisman M, Xu Y, Sanderson-Bongiovanni D & Soons P (2010) Loperamide and P-glycoprotein inhibition: assessment of the clinical relevance. *J Pharm Pharmacol*, 62, 401–412. [PubMed: 20604828]
- Vaughn P, Solik MM, Bagga S & Padanilam BJ (2016) Electrocardiographic Abnormalities, Malignant Ventricular Arrhythmias, and Cardiomyopathy Associated With Loperamide Abuse. *J Cardiovasc Electrophysiol*.
- Violin JD & Lefkowitz RJ (2007) Beta-arrestin-biased ligands at seven-transmembrane receptors. *Trends Pharmacol Sci*, 28, 416–422. [PubMed: 17644195]
- Wade PR, Palmer JM, McKenney S, Kenigs V, Chevalier K, Moore BA, Mabus JR, Saunders PR, Wallace NH, Schneider CR, Kimball ES, Breslin HJ, He W & Hornby PJ (2012) Modulation of gastrointestinal function by MuDelta, a mixed micro opioid receptor agonist/ micro opioid receptor antagonist. *British journal of pharmacology*, 167, 1111–1125. [PubMed: 22671931]
- Webster LR, Brenner DM, Barrett AC, Paterson C, Bortey E & Forbes WP (2015) Analysis of opioid-mediated analgesia in Phase III studies of methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain. *Journal of pain research*, 8, 771–780. [PubMed: 26586963]
- Williams JT, Ingram SL, Henderson G, Chavkin C, von Zastrow M, Schulz S, Koch T, Evans CJ & Christie MJ (2013) Regulation of mu-opioid receptors: desensitization, phosphorylation, internalization, and tolerance. *Pharmacological reviews*, 65, 223–254. [PubMed: 23321159]

Table 1.

Summary of opioid receptor localization and function in the gut

Opioid receptor	Cell type expression	Molecular targets	Functional consequence
	Myenteric inhibitory motoneurons (guinea pig stomach and small intestine)	K ⁺ channel activation Ca ²⁺ channel inhibition	Inhibit action potential firing and neurotransmitter release Decreased propulsive motility
	Myenteric excitatory motoneurons, inhibitory motoneurons and interneurons (guinea pig small intestine)	K ⁺ channel activation Ca ²⁺ channel inhibition	Inhibit action potential firing and neurotransmitter release Decreased propulsive motility
	Myenteric interneurons (guinea pig)	K ⁺ channel activation Ca ²⁺ channel inhibition	Inhibit action potential firing and neurotransmitter release Decreased propulsive motility
MOR	Submucosal secretomotor neurons (guinea pig ileum and distal colon)	K ⁺ channel activation Ca ²⁺ channel inhibition	Decreased water and electrolyte secretion
	Myenteric neurons (mouse); primary culture	Na ⁺ channel inhibition	Inhibit action potential firing Decreased propulsive motility
	Interstitial cells of Cajal (ICC)(rat, mouse)	K ⁺ ATP channel activation (mouse)	Inhibit pacemaker potentials
	Myenteric and submucosal neurons (human small and large intestine)	Not determined	Decreased water and electrolyte secretion
	Inhibitory motoneurons (human)	Not determined	Decreased muscle relaxation
	Rat myenteric and submucosal neurons	Not determined	Not determined.
	Submucosal secretomotor neurons (guinea pig ileum)	K ⁺ channel activation Ca ²⁺ channel inhibition	Decreased water and electrolyte secretion
	Submucosal secretomotor and vasomotor neurons (mouse small intestine)	Not determined	Not determined
DOR	Excitatory and inhibitory motoneurons (mouse small intestine)	Not determined	Not determined
	Inhibitory motoneurons (mouse colon)	Not determined	Not determined
	Interstitial cells of Cajal (ICC) (rat, mouse)	K ⁺ ATP channel activation (mouse)	Inhibit pacemaker potentials
	Excitatory motoneurons (human colon)	Not determined	Decreased neurogenic contraction
	Inhibitory motoneurons (human)	Not determined	Decreased propulsive motility
KOR	Myenteric motor neurons (guinea pig)	Ca ²⁺ channel inhibition	Inhibit neurotransmitter release Decreased neurogenic contraction and relaxation
	Excitatory and inhibitory motoneurons (human colon)	Not determined	Decreased propulsive motility
	Interstitial cells of Cajal (ICC)(rat)	Not determined	Functional data unavailable